Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350–473. https://doi.org/10.1016/j.jacc.2023.11.007.

Article  PubMed  PubMed Central  Google Scholar 

Alanaeme CJ, Bittner V, Brown TM, et al. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline. Am Heart J Plus. 2022;21:100201. https://doi.org/10.1016/j.ahjo.2022.100201.

Article  PubMed  PubMed Central  Google Scholar 

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/s0140-6736(10)61350-5.

Article  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. https://doi.org/10.1016/j.jacc.2018.11.003.

Article  PubMed  Google Scholar 

Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13(5):776–83. https://doi.org/10.1097/01.hjr.0000189805.76482.6e.

Article  PubMed  Google Scholar 

Fox KM, Tai MH, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380–8. https://doi.org/10.1007/s00392-017-1193-z.

Article  CAS  PubMed  Google Scholar 

März W, Dippel FW, Theobald K, Gorcyca K, Iorga ŞR, Ansell D. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99–107. https://doi.org/10.1016/j.atherosclerosis.2017.11.020.

Article  CAS  PubMed  Google Scholar 

Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184–96. https://doi.org/10.1016/j.ijcard.2016.09.075.

Article  PubMed  Google Scholar 

Laufs U, Karmann B, Pittrow D. Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol. 2016;105(9):783–90. https://doi.org/10.1007/s00392-016-0991-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(9):959–66. https://doi.org/10.1001/jamacardio.2017.2289.

Article  PubMed  PubMed Central  Google Scholar 

Navar AM, Shah NP, Shrader P, et al. Achievement of LDL-C <55 mg/dl among US adults: findings from the cvMOBIUS2 registry. Am Heart J. 2025;279:107–17. https://doi.org/10.1016/j.ahj.2024.06.012.

Article  CAS  PubMed  Google Scholar 

Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752–62. https://doi.org/10.1080/00325481.2022.2117498.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174.

Article  CAS  PubMed  Google Scholar 

Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won’t do! Drugs. 2016;76(12):1175–90. https://doi.org/10.1007/s40265-016-0613-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Annemans L, Stock JK, Chapman MJ. PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: challenges at the crossroads. J Clin Lipidol. 2019;13(5):714–20. https://doi.org/10.1016/j.jacl.2019.07.005.

Article  PubMed  Google Scholar 

Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol. 2021;15(1):202–11.e2. https://doi.org/10.1016/j.jacl.2020.11.004.

Article  PubMed  Google Scholar 

Saborowski M, Dölle M, Manns MP, Leitolf H, Zender S. Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohort. Cardiol J. 2018;25(1):32–41. https://doi.org/10.5603/CJ.a2017.0137.

Article  PubMed  Google Scholar 

Hines DM, Rane P, Patel J, Harrison DJ, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409–18. https://doi.org/10.2147/vhrm.S180496.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khvorova A. Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med. 2017;376(1):4–7. https://doi.org/10.1056/NEJMp1614154.

Article  CAS  PubMed  Google Scholar 

Novartis Pharmaceuticals Corporation. LEQVIO® (inclisiran). Highlights of prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214012s016lbl.pdf. Accessed Sept 30, 2025.

Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. https://doi.org/10.1056/nejmoa1912387.

Article  CAS  PubMed  Google Scholar 

Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–30. https://doi.org/10.1056/NEJMoa1913805.

Article  CAS  PubMed  Google Scholar 

Bertolet BD, Cabral KP, Sullenberger L, McAlister JL, Sandroni T, Patel DS. Clinical considerations for healthcare provider-administered lipid-lowering medications. Am J Cardiovasc Drugs. 2024;24(6):729–41. https://doi.org/10.1007/s40256-024-00665-1.

Article  PubMed  PubMed Central  Google Scholar 

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818–27. https://doi.org/10.1016/j.jacl.2023.09.005.

Article  PubMed  Google Scholar 

Padam P, Barton L, Wilson S, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):e002184. https://doi.org/10.1136/openhrt-2022-002184.

Article  PubMed  PubMed Central  Google Scholar 

Naoum I, Saliba W, Aker A, Zafrir B. Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service. J Clin Lipidol. 2024;18(5):e809–16. https://doi.org/10.1016/j.jacl.2024.05.003.

Article  PubMed  Google Scholar 

Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27. https://doi.org/10.1097/00005650-199801000-00004.